Pds Biotechnology Corp Stock Current Valuation
PDSB Stock | USD 2.09 0.11 5.00% |
Valuation analysis of PDS Biotechnology Corp helps investors to measure PDS Biotechnology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 309.2 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (3.17). Fundamental drivers impacting PDS Biotechnology's valuation include:
Price Book 3.5537 | Enterprise Value 53.1 M | Enterprise Value Ebitda (2.58) |
Undervalued
Today
Please note that PDS Biotechnology's price fluctuation is moderately volatile at this time. Calculation of the real value of PDS Biotechnology Corp is based on 3 months time horizon. Increasing PDS Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since PDS Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PDS Stock. However, PDS Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 2.09 | Real 6.31 | Target 19.14 | Hype 2.06 | Naive 1.5 |
The real value of PDS Stock, also known as its intrinsic value, is the underlying worth of PDS Biotechnology Corp Company, which is reflected in its stock price. It is based on PDS Biotechnology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of PDS Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of PDS Biotechnology Corp helps investors to forecast how PDS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PDS Biotechnology more accurately as focusing exclusively on PDS Biotechnology's fundamentals will not take into account other important factors: PDS Biotechnology Corp Company Current Valuation Analysis
PDS Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current PDS Biotechnology Current Valuation | 53.1 M |
Most of PDS Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PDS Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PDS Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for PDS Biotechnology is extremely important. It helps to project a fair market value of PDS Stock properly, considering its historical fundamentals such as Current Valuation. Since PDS Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PDS Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PDS Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, PDS Biotechnology Corp has a Current Valuation of 53.1 M. This is 99.63% lower than that of the Biotechnology sector and 98.86% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.68% higher than that of the company.
PDS Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PDS Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PDS Biotechnology could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics of similar companies.PDS Biotechnology is currently under evaluation in current valuation category among its peers.
PDS Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of PDS Biotechnology from analyzing PDS Biotechnology's financial statements. These drivers represent accounts that assess PDS Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PDS Biotechnology's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 12.9M | 35.8M | 207.3M | 377.5M | 339.8M | 356.7M | |
Enterprise Value | 738.7K | 7.6M | 142.6M | 327.2M | 294.4M | 309.2M |
PDS Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PDS Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PDS Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
PDS Fundamentals
Return On Equity | -1.28 | ||||
Return On Asset | -0.4 | ||||
Current Valuation | 53.1 M | ||||
Shares Outstanding | 37.41 M | ||||
Shares Owned By Insiders | 3.99 % | ||||
Shares Owned By Institutions | 12.35 % | ||||
Number Of Shares Shorted | 4.47 M | ||||
Price To Earning | 24.70 X | ||||
Price To Book | 3.55 X | ||||
EBITDA | (40.08 M) | ||||
Net Income | (42.94 M) | ||||
Cash And Equivalents | 52.98 M | ||||
Cash Per Share | 1.86 X | ||||
Total Debt | 23.85 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 12.34 X | ||||
Book Value Per Share | 0.79 X | ||||
Cash Flow From Operations | (33.64 M) | ||||
Short Ratio | 10.47 X | ||||
Earnings Per Share | (1.17) X | ||||
Price To Earnings To Growth | (0.05) X | ||||
Target Price | 11.9 | ||||
Number Of Employees | 25 | ||||
Beta | 1.93 | ||||
Market Capitalization | 78.19 M | ||||
Total Asset | 59.39 M | ||||
Retained Earnings | (144.5 M) | ||||
Working Capital | 45.43 M | ||||
Current Asset | 39.11 M | ||||
Current Liabilities | 4.54 M | ||||
Net Asset | 59.39 M |
About PDS Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PDS Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PDS Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PDS Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out PDS Biotechnology Piotroski F Score and PDS Biotechnology Altman Z Score analysis. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.